120 related articles for article (PubMed ID: 35229668)
1. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Hauser SL; Zielman R; Das Gupta A; Xi J; Stoneman D; Karlsson G; Robertson D; Cohen JA; Kappos L
Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis.
Kramer J; Linker R; Paling D; Czaplinski A; Hoffmann O; Yong VW; Barker N; Ross AP; Lucassen E; Gufran M; Hu X; Zielman R; Seifer G; Vermersch P
Mult Scler J Exp Transl Clin; 2023; 9(4):20552173231203816. PubMed ID: 37829441
[TBL] [Abstract][Full Text] [Related]
4. Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study.
D'Amico E; Zanghì A; Fantozzi R; Centonze D; Avolio C
Curr Neuropharmacol; 2023; 21(12):2563-2566. PubMed ID: 37534789
[TBL] [Abstract][Full Text] [Related]
5. [Over one year of B‑cell targeted therapy with Ofatumumab s.c.: first results of a prospective, patient-centered real-world observational study].
Klimas R; Karl AS; Poser PL; Sgodzai M; Theile-Ochel S; Gisevius B; Faissner S; Nastos I; Gold R; Motte J
Nervenarzt; 2023 Oct; 94(10):923-933. PubMed ID: 37042954
[TBL] [Abstract][Full Text] [Related]
6. Concurrent management of multiple sclerosis and natalizumab-induced hepatitis with ofatumumab: a case report.
Haggiag S; Giannelli V; Prosperini L; Cruciani A; Baiocchini A; Ruggieri S; Pellicelli A; Gasperini C; Tortorella C
Neurol Sci; 2024 Jun; ():. PubMed ID: 38861049
[No Abstract] [Full Text] [Related]
7. Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.
Kölsche T; Willison AG; Meuth SG; Pawlitzki M; Horbrügger M; Skripuletz T; Meller S; Pfeuffer S
Mult Scler; 2024 Jun; ():13524585241260564. PubMed ID: 38877846
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner J; Hauser SL; Bar-Or A; Montalban X; Cohen JA; Cross AH; Deiva K; Ganjgahi H; Häring DA; Li B; Pingili R; Ramanathan K; Su W; Willi R; Kieseier B; Kappos L
Mult Scler; 2022 Sep; 28(10):1562-1575. PubMed ID: 35266417
[TBL] [Abstract][Full Text] [Related]
9. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
[TBL] [Abstract][Full Text] [Related]
10. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
[TBL] [Abstract][Full Text] [Related]
11. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
Okuda DT; Kantarci O; Lebrun-Frénay C; Sormani MP; Azevedo CJ; Bovis F; Hua LH; Amezcua L; Mowry EM; Hotermans C; Mendoza J; Walsh JS; von Hehn C; Vargas WS; Donlon S; Naismith RT; Okai A; Pardo G; Repovic P; Stüve O; Siva A; Pelletier D
Ann Neurol; 2023 Mar; 93(3):604-614. PubMed ID: 36401339
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
Cross AH; Delgado S; Habek M; Davydovskaya M; Ward BJ; Cree BAC; Totolyan N; Pingili R; Mancione L; Hu X; Sullivan R; Su W; Zielman R; Gupta AD; Montalban X; Winthrop K
Neurol Ther; 2022 Jun; 11(2):741-758. PubMed ID: 35284994
[TBL] [Abstract][Full Text] [Related]
14. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab.
Ziemssen T; Groth M; Ettle B; Bopp T
Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560576
[TBL] [Abstract][Full Text] [Related]
15. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
[TBL] [Abstract][Full Text] [Related]
16. Usability validation of the Sensoready
Terlizzi RD; King M; Blohm C
Ther Deliv; 2023 Apr; 14(4):259-268. PubMed ID: 37435652
[No Abstract] [Full Text] [Related]
17. Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.
Laurent SA; Strauli NB; Eggers EL; Wu H; Michel B; Demuth S; Palanichamy A; Wilson MR; Sirota M; Hernandez RD; Cree BAC; Herman AE; von Büdingen HC
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37094998
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
[TBL] [Abstract][Full Text] [Related]
19. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.
Saidha S; Bell J; Harold S; Belisario JM; Hawe E; Shao Q; Wyse K; Maiese EM
Neurol Sci; 2023 May; 44(5):1515-1532. PubMed ID: 36648561
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
